Beryl Drugs Profit & Loss Annual

BSE: 524606 | NSE: - | ISIN: INE415H01017 | Sector: Biotechnology & Drugs

17.88 -0.94 (-4.99%)Updated : 24 Jun 2025

Interim Data

Annual Data

Fiscal Period	2025	2024	2023	2022
Period End Date	Mar 25	Mar 24	Mar 23	Mar 22
Revenue	21.15	26.73	26.89	14.60
Total Revenue	21.15	26.73	26.89	14.60
Costof Revenue Total	10.78	13.15	14.54	8.40
Gross Profit	10.36	13.58	12.35	6.20
Selling/ General/ Admin Expenses Total	2.21	1.93	1.70	1.31
Depreciation/ Amortization	1.25	1.19	0.80	1.07
Other Operating Expenses Total	6.92	9.38	8.71	4.48
Total Operating Expense	21.16	25.65	25.76	15.28
Operating Income	-0.01	1.08	1.13	-0.68
Interest Inc( Exp) Net- Non- Op Total	-0.53	-0.45	-0.42	-0.40
Other Net	1.41	0.37	0.27	0.12
Net Income Before Taxes	0.87	1.01	0.98	-0.95
Provisionfor Income Taxes	0.29	0.24	0.22	-0.29
Net Income After Taxes	0.58	0.77	0.77	-0.66
Net Income Before Extra Items	0.58	0.77	0.77	-0.66
Net Income	0.58	0.77	0.77	-0.66
Income Availableto Com Excl Extra Ord	0.58	0.77	0.77	-0.66
Income Availableto Com Incl Extra Ord	0.58	0.77	0.77	-0.66
Diluted Net Income	0.58	0.77	0.77	-0.66
Diluted Weighted Average Shares	0.51	0.51	0.51	0.51
Diluted EPS Excluding Extra Ord Items	1.14	1.52	1.51	-1.30
Diluted Normalized EPS	1.14	1.50	1.51	-1.30
period Length	12.00	12.00	12.00	12.00
period Type	-	-	-	-
Interest Exp( Inc) Net- Operating Total	-	0.01	0.01	0.02
Gain( Loss)on Saleof Assets	-	0.01	-	-
Total Adjustmentsto Net Income	-	-	0.00	-
Dilution Adjustment	-	-	0.00	-